Top

Current Obesity Reports

Published in:

01-09-2019 | Obesity | Metabolism (M Dalamaga, Section Editor)

Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives

Authors: Cherlyn Ding, Faidon Magkos

Published in: Current Obesity Reports | Issue 3/2019

Abstract

Purpose of Review

The neurohypophysial endocrine system is identified here as a potential target for therapeutic interventions toward improving obesity-related metabolic dysfunction, given its coinciding pleiotropic effects on psychological, neurological and metabolic systems that are disrupted in obesity.

Recent Findings

Copeptin, the C-terminal portion of the precursor of arginine-vasopressin, is positively associated with body mass index and risk of type 2 diabetes. Plasma oxytocin is decreased in obesity and several other conditions of abnormal glucose homeostasis. Recent data also show non-classical tissues, such as myocytes, hepatocytes and β-cells, exhibit responses to oxytocin and vasopressin receptor binding that may contribute to alterations in metabolic function.

Summary

The modulation of anorexigenic and orexigenic pathways appears to be the dominant mechanism underlying the effects of oxytocin and vasopressin on body weight regulation; however, there are apparent limitations associated with their use in direct pharmacological applications. A clearer picture of their wider physiological effects is needed before either system can be considered for therapeutic use.

Hatton GI. Emerging concepts of structure-function dynamics in adult brain: the hypothalamo-neurohypophysial system. Prog Neurobiol. 1990;34(6):437–504. https://doi.org/10.1016/0301-0082(90)90017-B.CrossRefPubMed

Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 1993;14(2):76–122. https://doi.org/10.1006/frne.1993.1004.CrossRefPubMed

Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12(9):524–38. https://doi.org/10.1038/nrn3044.CrossRefPubMed

• Ding C, Leow MK, Magkos F. Oxytocin in metabolic homeostasis: implications for obesity and diabetes management. Obes Rev. 2019;20(1):22–40. https://doi.org/10.1111/obr.12757 This paper highlights recent developments in the role of oxytocin in obesity and T2DM management. CrossRefPubMed

• Nakamura K, Velho G, Bouby N. Vasopressin and metabolic disorders: translation from experimental models to clinical use. J Intern Med. 2017;282(4):298–309. https://doi.org/10.1111/joim.12649 This paper highlights the mechanistic underpinnings of the vasopressin-hydration axis in glucose homeostasis. CrossRefPubMed

Butland B, Jebb S, Kopelman P, McPherson K, Thomas S, Mardell J et al. Foresight. Tackling obesities: future choices. Project report. Foresight Tackling obesities: future choices Project report. 2007.

Smith RW, McCann SM. Alterations in food and water intake after hypothalamic lesions in the rat. Am J Phys. 1962;203(2):366–70. https://doi.org/10.1152/ajplegacy.1962.203.2.366.CrossRef

Enhörning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes. 2012;37:598. https://doi.org/10.1038/ijo.2012.88.CrossRef

Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab. 2015;100(9):3332–9. https://doi.org/10.1210/JC.2015-2362.CrossRefPubMedPubMedCentral

10.

Zhu FX, Wu HL, Tu KS, Chen JX, Zhang M, Shi C. Serum levels of copeptin are associated with type 2 diabetes and diabetic complications in Chinese population. J Diabetes Complicat. 2016;30(8):1566–70. https://doi.org/10.1016/j.jdiacomp.2016.07.017.CrossRefPubMed

11.

Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94(7):2558–64. https://doi.org/10.1210/jc.2008-2278.CrossRefPubMedPubMedCentral

12.

Enhörning S, Leosdottir M, Wallström P, Gullberg B, Berglund G, Wirfält E, et al. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr. 2009;89(1):400–6. https://doi.org/10.3945/ajcn.2008.26382.CrossRefPubMed

13.

Enhorning S, Sjogren M, Hedblad B, Nilsson PM, Struck J, Melander O. Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus. Eur J Endocrinol. 2016;174(1):69–75. https://doi.org/10.1530/EJE-15-0781.CrossRefPubMedPubMedCentral

14.

Santoso P, Nakata M, Ueta Y, Yada T. Suprachiasmatic vasopressin to paraventricular oxytocin neurocircuit in the hypothalamus relays light reception to inhibit feeding behavior. Am J Physiol Endocrinol Metab. 2018;315(4):E478–E88. https://doi.org/10.1152/ajpendo.00338.2016.CrossRefPubMed

15.

Yarkov A, Montero S, Lemus M, Roces de Alvarez-Buylla E, Alvarez-Buylla R. Arginine-vasopressin in nucleus of the tractus solitarius induces hyperglycemia and brain glucose retention. Brain Res. 2001;902(2):212–22. https://doi.org/10.1016/S0006-8993(01)02404-0.CrossRefPubMed

16.

Montero S, Mendoza H, Valles V, Lemus M, Alvarez-Buylla R, Alvarez-Buylla ER. Arginine-vasopressin mediates central and peripheral glucose regulation in response to carotid body receptor stimulation with Na-cyanide. J Appl Physiol. 2006;100(6):1902–9. https://doi.org/10.1152/japplphysiol.01414.2005.CrossRefPubMed

17.

Chong AC, Vogt MC, Hill AS, Bruning JC, Zeltser LM. Central insulin signaling modulates hypothalamus-pituitary-adrenal axis responsiveness. Mol Metab. 2015;4(2):83–92. https://doi.org/10.1016/j.molmet.2014.12.001.CrossRefPubMed

18.

Plotsky PM, Bruhn TO, Vale W. Hypophysiotropic regulation of adrenocorticotropin secretion in response to insulin-induced hypoglycemia. Endocrinology. 1985;117(1):323–9. https://doi.org/10.1210/endo-117-1-323.CrossRefPubMed

19.

Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes. 1979;28(5):503–8. https://doi.org/10.2337/diab.28.5.503.CrossRefPubMed

20.

Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, et al. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol. 1985;22(4):463–8. https://doi.org/10.1111/j.1365-2265.1985.tb00145.x.CrossRef

21.

Chiodera P, Volpi R, Capretti L, Speroni G, Marcato A, Rossi G, et al. Hypoglycemia-induced arginine vasopressin and oxytocin release is mediated by glucoreceptors located inside the blood-brain barrier. Neuroendocrinology. 1992;55(6):655–9. https://doi.org/10.1159/000126185.CrossRefPubMed

22.

Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care. 2013;36(10):3201–7. https://doi.org/10.2337/dc12-2165.CrossRefPubMedPubMedCentral

23.

Brooks DP, Nutting DF, Crofton JT, Share L. Vasopressin in rats with genetic and streptozocin-induced diabetes. Diabetes. 1989;38(1):54–7. https://doi.org/10.2337/diab.38.1.54.CrossRefPubMed

24.

Yi SS, Hwang IK, Kim YN, Kim IY, Pak S-I, Lee IS, et al. Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats. Neurochem Res. 2007;33(5):833. https://doi.org/10.1007/s11064-007-9519-2.CrossRefPubMed

25.

Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus M-F, et al. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia. 2015;58(5):1081–90. https://doi.org/10.1007/s00125-015-3496-9.CrossRefPubMed

26.

Masuki S, Mori M, Tabara Y, Miki T, Sakurai A, Morikawa M, et al. Vasopressin V1a receptor polymorphism and interval walking training effects in middle-aged and older people. Hypertension. 2010;55(3):747–54. https://doi.org/10.1161/HYPERTENSIONAHA.109.147728.CrossRefPubMed

27.

Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, et al. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol. 2007;584(Pt 1):235–44. https://doi.org/10.1113/jphysiol.2007.136481.CrossRefPubMedPubMedCentral

28.

Hiroyama M, Fujiwara Y, Nakamura K, Aoyagi T, Mizutani R, Sanbe A, et al. Altered lipid metabolism in vasopressin V1B receptor-deficient mice. Eur J Pharmacol. 2009;602(2–3):455–61. https://doi.org/10.1016/j.ejphar.2008.11.043.CrossRefPubMed

29.

Klement J, Ott V, Rapp K, Brede S, Piccinini F, Cobelli C, et al. Oxytocin improves beta-cell responsivity and glucose tolerance in healthy men. Diabetes. 2016. https://doi.org/10.2337/db16-0569.

30.

Lawson EA. The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol. 2017;13(12):700–9. https://doi.org/10.1038/nrendo.2017.115.CrossRefPubMedPubMedCentral

31.

Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One. 2013;8(5):e61477. https://doi.org/10.1371/journal.pone.0061477.CrossRefPubMedPubMedCentral

32.

Lawson EA, Marengi DA, DeSanti RL, Holmes TM, Schoenfeld DA, Tolley CJ. Oxytocin reduces caloric intake in men. Obesity. 2015;23(5):950–6. https://doi.org/10.1002/oby.21069.CrossRefPubMed

33.

Ott V, Finlayson G, Lehnert H, Heitmann B, Heinrichs M, Born J, et al. Oxytocin reduces reward-driven food intake in humans. Diabetes. 2013;62(10):3418–25. https://doi.org/10.2337/db13-0663.CrossRefPubMedPubMedCentral

34.

Thienel M, Fritsche A, Heinrichs M, Peter A, Ewers M, Lehnert H, et al. Oxytocin’s inhibitory effect on food intake is stronger in obese than normal-weight men. Int J Obes. 2016;40:1707. https://doi.org/10.1038/ijo.2016.149.CrossRef

35.

Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier A-L, Petrosino S, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One. 2011;6(9):e25565. https://doi.org/10.1371/journal.pone.0025565.CrossRefPubMedPubMedCentral

36.

Olson BR, Drutarosky MD, Chow MS, Hruby VJ, Stricker EM, Verbalis JG. Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats. Peptides. 1991;12(1):113–8. https://doi.org/10.1016/0196-9781(91)90176-P.CrossRefPubMed

37.

Zhang G, Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab. 2011;301(5):E1004–12. https://doi.org/10.1152/ajpendo.00196.2011.CrossRefPubMedPubMedCentral

38.

Chiodera P, Coiro V, Camellini L, Rossi G, Pignatti D, Volpi R, et al. Effect of pharmacological doses of oxytocin on insulin response to glucose in normal man. Horm Res Paediatr. 1984;20(2):150–4.CrossRef

39.

Paolisso G, Pizza G, De Riu S, Marrazzo G, Sgambato S, Giugliano D, et al. Effects of oxytocin upon the endocrine pancreas secretion and glucose turnover in normal man. Eur J Endocrinol. 1990;123(5):504–10. https://doi.org/10.1530/acta.0.1230504.CrossRef

40.

Maestrini S, Mele C, Mai S, Vietti R, Di Blasio A, Castello L, et al. Plasma oxytocin concentration in pre- and postmenopausal women: its relationship with obesity, body composition and metabolic variables. Obes Facts. 2018;11(5):429–39. https://doi.org/10.1159/000492001.CrossRefPubMedPubMedCentral

41.

Björkstrand E, Eriksson M, Uvnäs-Moberg K. Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Neuroendocrinology. 1996;63(4):377–83.CrossRefPubMed

42.

Altirriba J, Poher A-L, Caillon A, Arsenijevic D, Veyrat-Durebex C, Lyautey J, et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology. 2014;155(11):4189–201. https://doi.org/10.1210/en.2014-1466.CrossRefPubMed

43.

Saravani R, Esmaeeli E, Kordi Tamendani M, Nejad MN. Oxytocin receptor gene polymorphisms in patients with diabetes. Gene, Cell Tissue. 2015;2(2):e60171. https://doi.org/10.17795/gct-27904.CrossRef

44.

Fujiwara Y, Hiroyama M, Sanbe A, Yamauchi J, Tsujimoto G, Tanoue A. Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. J Endocrinol. 2007;192(2):361–9. https://doi.org/10.1677/joe.1.06864.CrossRefPubMed

45.

Naylor AM, Ruwe WD, Veale WL. Thermoregulatory actions of centrally-administered vasopressin in the rat. Neuropharmacology. 1986;25(7):787–94. https://doi.org/10.1016/0028-3908(86)90097-3.CrossRefPubMed

46.

Paro FM, Almeida MC, Carnio EC, Branco LG. Role of L-glutamate in systemic AVP-induced hypothermia. J Appl Physiol (1985). 2003;94(1):271–7. https://doi.org/10.1152/japplphysiol.00291.2002.CrossRef

47.

Linggonegoro DW, Sandgren JA, Claflin KE, Perschbacher KJ, Ni J, Pearson NA, et al. Physiological significance of angiotensin AT1A receptors in vasopressin-producing cells. FASEB J. 2017;31(1_supplement):853.1-.1. https://doi.org/10.1096/fasebj.31.1_supplement.853.1.CrossRef

48.

Daikoku R, Kunitake T, Kato K, Tanoue A, Tsujimoto G, Kannan H. Body water balance and body temperature in vasopressin V1b receptor knockout mice. Auton Neurosci. 2007;136(1–2):58–62. https://doi.org/10.1016/j.autneu.2007.04.002.CrossRefPubMed

49.

Zhang G, Bai H, Zhang H, Dean C, Wu Q, Li J, et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron. 2011;69(3):523–35. https://doi.org/10.1016/j.neuron.2010.12.036.CrossRefPubMedPubMedCentral

50.

Lawson EA, Ackerman KE, Slattery M, Marengi DA, Clarke H, Misra M. Oxytocin secretion is related to measures of energy homeostasis in young amenorrheic athletes. J Clin Endocrinol Metab. 2014;99(5):E881–5. https://doi.org/10.1210/jc.2013-4136.CrossRefPubMedPubMedCentral

51.

Blevins JE, Graham JL, Morton GJ, Bales KL, Schwartz MW, Baskin DG, et al. Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol. 2015;308(5):R431–8. https://doi.org/10.1152/ajpregu.00441.2014.CrossRefPubMed

52.

• Enhörning S, Melander O. The vasopressin system in the risk of diabetes and cardiorenal disease, and hydration as a potential lifestyle intervention. Ann Nutr Metab. 2018;72 (suppl 2)(2):21–7. https://doi.org/10.1159/000488304 This paper highlights key evidence regarding vasopressin’s role in metabolic dysfunction. CrossRef

53.

Rofe AM, Williamson DH. Metabolic effects of vasopressin infusion in the starved rat. Reversal of ketonaemia. Biochem J. 1983;212(1):231–9. https://doi.org/10.1042/bj2120231.CrossRefPubMedPubMedCentral

54.

Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K, et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol. 2007;21(1):247–58. https://doi.org/10.1210/me.2006-0069.CrossRefPubMed

55.

Chikanza IC, Petrou P, Chrousos G. Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann N Y Acad Sci. 2000;917(1):825–34. https://doi.org/10.1111/j.1749-6632.2000.tb05448.x.CrossRefPubMed

56.

Reder AT. Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology. 1992;77(3):436–42.PubMedPubMedCentral

57.

Kuchler S, Perwitz N, Schick RR, Klein J, Westphal S. Arginine-vasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes. Regul Pept. 2010;164(2–3):126–32. https://doi.org/10.1016/j.regpep.2010.05.016.CrossRefPubMed

58.

McMahon PJ, Proctor KG. Vasopressin attenuates TNF-mediated inflammation in the rat cremaster microcirculation. J Trauma. 2009;67(3):461–73; discussion 73-5. https://doi.org/10.1097/TA.0b013e3181aa01e4.CrossRefPubMed

59.

Park J, Eo EY, Lee K-H, Park JS, Lee J-H, Yoo C-G, et al. The anti-inflammatory effect of arginine-vasopressin on lipopolysaccharide-induced IκBα/nuclear factor-κB cascade. Korean J Crit Care Med. 2015;30(3):151–7. https://doi.org/10.4266/kjccm.2015.30.3.151.CrossRef

60.

Peng T-C, Huang C-J. Vasopressin inhibits endotoxin-induced upregulation of inflammatory mediators in activated macrophages. Tzu Chi Med J. 2013;25(3):150–4. https://doi.org/10.1016/j.tcmj.2013.04.003.CrossRef

61.

Szeto A, Sun-Suslow N, Mendez AJ, Hernandez RI, Wagner KV, McCabe PM. Regulation of the macrophage oxytocin receptor in response to inflammation. Am J Physiol Endocrinol Metab. 2017;312(3):E183–E9. https://doi.org/10.1152/ajpendo.00346.2016.CrossRefPubMedPubMedCentral

62.

Szeto A, Nation DA, Mendez AJ, Dominguez-Bendala J, Brooks LG, Schneiderman N, et al. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab. 2008;295(6):E1495–501. https://doi.org/10.1152/ajpendo.90718.2008.CrossRefPubMedPubMedCentral

63.

Gold PW, Kaye W, Robertson GL, Ebert M. Abnormalities in plasma and cerebrospinal-fluid arginine vasopressin in patients with anorexia nervosa. N Engl J Med. 1983;308(19):1117–23. https://doi.org/10.1056/NEJM198305123081902.CrossRefPubMed

64.

Wren AM, Small CJ, Abbott CR, Jethwa PH, Kennedy AR, Murphy KG, et al. Hypothalamic actions of neuromedin U. Endocrinology. 2002;143(11):4227–34. https://doi.org/10.1210/en.2002-220308.CrossRefPubMed

65.

Bäckberg M, Hervieu G, Wilson S, Meister B. Orexin receptor-1 (OX-R1) immunoreactivity in chemically identified neurons of the hypothalamus: focus on orexin targets involved in control of food and water intake. Eur J Neurosci. 2002;15(2):315–28. https://doi.org/10.1046/j.0953-816x.2001.01859.x.CrossRefPubMed

66.

Dhillo WS, Small CJ, Jethwa PH, Russell SH, Gardiner JV, Bewick GA, et al. Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology. 2003;144(4):1420–5. https://doi.org/10.1210/en.2002-220902.CrossRefPubMed

67.

Langhans W, Delprete E, Scharrer E. Mechanisms of vasopressin’s anorectic effect. Physiol Behav. 1991;49(1):169–76. https://doi.org/10.1016/0031-9384(91)90251-I.CrossRefPubMed

68.

Aravich PF, Sladek CD. Vasopressin and glucoprivic-feeding behavior: a new perspective on an ‘old’ peptide. Brain Res. 1986;385(2):245–52. https://doi.org/10.1016/0006-8993(86)91070-x.CrossRefPubMed

69.

Bachner-Melman R, Zohar AH, Elizur Y, Nemanov L, Gritsenko I, Konis D, et al. Association between a vasopressin receptor AVPR1A promoter region microsatellite and eating behavior measured by a self-report questionnaire (Eating Attitudes Test) in a family-based study of a nonclinical population. Int J Eat Disord. 2004;36(4):451–60. https://doi.org/10.1002/eat.20049.CrossRefPubMed

70.

Plessow F, Marengi DA, Perry SK, Felicione JM, Franklin R, Holmes TM, et al. Effects of intranasal oxytocin on the blood oxygenation level-dependent signal in food motivation and cognitive control pathways in overweight and obese men. Neuropsychopharmacology. 2018;43(3):638–45. https://doi.org/10.1038/npp.2017.226.CrossRefPubMed

71.

Spetter MS, Feld GB, Thienel M, Preissl H, Hege MA, Hallschmid M. Oxytocin curbs calorie intake via food-specific increases in the activity of brain areas that process reward and establish cognitive control. Sci Rep. 2018;8(1):2736. https://doi.org/10.1038/s41598-018-20963-4.CrossRefPubMedPubMedCentral

72.

van der Klaauw AA, Ziauddeen H, Keogh JM, Henning E, Dachi S, Fletcher PC, et al. Oxytocin administration suppresses hypothalamic activation in response to visual food cues. Sci Rep. 2017;7(1):4266. https://doi.org/10.1038/s41598-017-04600-0.CrossRefPubMedPubMedCentral

73.

Demitrack MA, Lesem MD, Listwak SJ, Brandt HA, Jimerson DC, Gold PW. CSF oxytocin in anorexia nervosa and bulimia nervosa: clinical and pathophysiologic considerations. Am J Psychiatry. 1990;147(7):882–6. https://doi.org/10.1176/ajp.147.7.882.CrossRefPubMed

74.

Mullis K, Kay K, Williams DL. Oxytocin action in the ventral tegmental area affects sucrose intake. Brain Res. 2013;1513:85–91. https://doi.org/10.1016/j.brainres.2013.03.026.CrossRefPubMedPubMedCentral

75.

• Blevins JE, Thompson BW, Anekonda VT, Ho JM, Graham JL, Roberts ZS, et al. Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization. Am J Physiol Regul Integr Comp Physiol. 2016;310(7):R640–58. https://doi.org/10.1152/ajpregu.00220.2015 This paper provides evidence for the role of oxytocin signalling in the CNS and its potential use as a target for treating diet-induced obesity. CrossRefPubMedPubMedCentral

76.

Maejima Y, Iwasaki Y, Yamahara Y, Kodaira M, Sedbazar U, Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY). 2011;3(12):1169–77. https://doi.org/10.18632/aging.100408.CrossRef

77.

Iwasaki Y, Maejima Y, Suyama S, Yoshida M, Arai T, Katsurada K, et al. Peripheral oxytocin activates vagal afferent neurons to suppress feeding in normal and leptin-resistant mice: a route for ameliorating hyperphagia and obesity. Am J Physiol Regul Integr Comp Physiol. 2015;308(5):R360–9. https://doi.org/10.1152/ajpregu.00344.2014.CrossRefPubMed

78.

Arletti R, Benelli A, Bertolini A. Influence of oxytocin on feeding behavior in the rat. Peptides. 1989;10(1):89–93. https://doi.org/10.1016/0196-9781(89)90082-X.CrossRefPubMed

79.

Davis C, Patte K, Zai C, Kennedy JL. Polymorphisms of the oxytocin receptor gene and overeating: the intermediary role of endophenotypic risk factors. Nutr Diabetes. 2017;7(5):e279. https://doi.org/10.1038/nutd.2017.24.CrossRefPubMedPubMedCentral

80.

Masuki S, Sumiyoshi E, Koshimizu TA, Qian J, Higuchi K, Tsujimoto G, et al. Voluntary locomotion linked with cerebral activation is mediated by vasopressin V1a receptors in free-moving mice. J Physiol. 2013;591(14):3651–65. https://doi.org/10.1113/jphysiol.2013.251876.CrossRefPubMedPubMedCentral

81.

Tsunematsu T, Fu LY, Yamanaka A, Ichiki K, Tanoue A, Sakurai T, et al. Vasopressin increases locomotion through a V1a receptor in orexin/hypocretin neurons: implications for water homeostasis. J Neurosci. 2008;28(1):228–38. https://doi.org/10.1523/JNEUROSCI.3490-07.2008.CrossRefPubMedPubMedCentral

82.

Ettenberg A, Vanderkooy D, Lemoal M, Koob G, Bloom F. Can aversive properties of (peripherally-injected) vasopressin account for its putative role in memory? Behav Brain Res. 1983;7(3):331–50. https://doi.org/10.1016/0166-4328(83)90024-4.CrossRefPubMed

83.

Masuki S, Mori M, Tabara Y, Sakurai A, Hashimoto S, Morikawa M, et al. The factors affecting adherence to a long-term interval walking training program in middle-aged and older people. J Appl Physiol (1985). 2015;118(5):595–603. https://doi.org/10.1152/japplphysiol.00819.2014.CrossRef

84.

Barraza JA, Grewal NS, Ropacki S, Perez P, Gonzalez A, Zak PJ. Effects of a 10-day oxytocin trial in older adults on health and well-being. Exp Clin Psychopharmacol. 2013;21(2):85–92. https://doi.org/10.1037/a0031581.CrossRefPubMed

85.

Nervi C, Benedetti L, Minasi A, Molinaro M, Adamo S. Arginine-vasopressin induces differentiation of skeletal myogenic cells and up-regulation of myogenin and Myf-5. Cell Growth Differ. 1995;6(1):81–9.PubMed

86.

Costa A, Rossi E, Scicchitano BM, Coletti D, Moresi V, Adamo S. Neurohypophyseal hormones: novel actors of striated muscle development and homeostasis. Eur J Transl Myol. 2014;24(3):3790. https://doi.org/10.4081/ejtm.2014.3790.CrossRefPubMedPubMedCentral

87.

Toschi A, Severi A, Coletti D, Catizone A, Musaro A, Molinaro M, et al. Skeletal muscle regeneration in mice is stimulated by local overexpression of V1a-vasopressin receptor. Mol Endocrinol. 2011;25(9):1661–73. https://doi.org/10.1210/me.2011-1049.CrossRefPubMedPubMedCentral

88.

Costa A, Toschi A, Murfuni I, Pelosi L, Sica G, Adamo S, et al. Local overexpression of V1a-vasopressin receptor enhances regeneration in tumor necrosis factor-induced muscle atrophy. Biomed Res Int. 2014;2014:235426. https://doi.org/10.1155/2014/235426.CrossRefPubMedPubMedCentral

89.

Breton C, Haenggeli C, Barberis C, Heitz F, Bader CR, Bernheim L, et al. Presence of functional oxytocin receptors in cultured human myoblasts. J Clin Endocrinol Metab. 2002;87(3):1415–8. https://doi.org/10.1210/jcem.87.3.8537.CrossRefPubMed

90.

Lee ES, Uhm K-O, Lee YM, Kwon J, Park S-H, Soo KH. Oxytocin stimulates glucose uptake in skeletal muscle cells through the calcium–CaMKK–AMPK pathway. Regul Pept. 2008;151(1):71–4. https://doi.org/10.1016/j.regpep.2008.05.001.CrossRefPubMed

91.

Berio E, Divari S, Starvaggi Cucuzza L, Biolatti B, Cannizzo FT. 17beta-estradiol upregulates oxytocin and the oxytocin receptor in C2C12 myotubes. PeerJ. 2017;5:e3124. https://doi.org/10.7717/peerj.3124.CrossRefPubMedPubMedCentral

92.

Weaver JU, Kopelman PG, McLoughlin L, Forslingt ML, Grossman A. Hyperactivity of the hypothalamo-pituitary-adrenal axis in obesity: a study of ACTH, AVP, β-lipotrophin and cortisol responses to insulin-induced hypoglycaemia. Clin Endocrinol. 1993;39(3):345–50. https://doi.org/10.1111/j.1365-2265.1993.tb02375.x.CrossRef

93.

Tran TD, Yao S, Hsu WH, Gimble JM, Bunnell BA, Cheng H. Arginine vasopressin inhibits adipogenesis in human adipose-derived stem cells. Mol Cell Endocrinol. 2015;406:1–9. https://doi.org/10.1016/j.mce.2015.02.009.CrossRefPubMedPubMedCentral

94.

Bush NR, Allison AL, Miller AL, Deardorff J, Adler NE, Boyce WT. Socioeconomic disparities in childhood obesity risk: association with an oxytocin receptor polymorphism. JAMA Pediatr. 2017;171(1):61–7. https://doi.org/10.1001/jamapediatrics.2016.2332.CrossRefPubMed

95.

Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A. 2006;103(20):7807–12. https://doi.org/10.1073/pnas.0600875103.CrossRefPubMedPubMedCentral

96.

Lee B, Yang C, Chen TH, al-Azawi N, Hsu WH. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am J Phys. 1995;269(6 Pt 1):E1095–100. https://doi.org/10.1152/ajpendo.1995.269.6.E1095.CrossRef

97.

Abu-Basha EA, Yibchok-anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism. 2002;51(9):1184–90. https://doi.org/10.1053/meta.2002.34052.CrossRefPubMed

98.

O'Carroll AM, Howell GM, Roberts EM, Lolait SJ. Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic beta-cells. J Endocrinol. 2008;197(2):231–9. https://doi.org/10.1677/JOE-07-0645.CrossRefPubMedPubMedCentral

99.

Mohan S, Khan D, Moffett RC, Irwin N, Flatt PR. Oxytocin is present in islets and plays a role in beta-cell function and survival. Peptides. 2018;100:260–8. https://doi.org/10.1016/j.peptides.2017.12.019.CrossRefPubMed

100.

Hughes BP, Rye KA, Pickford LB, Barritt GJ, Chalmers AH. A transient increase in diacylglycerols is associated with the action of vasopressin on hepatocytes. Biochem J. 1984;222(2):535–40. https://doi.org/10.1042/bj2220535.CrossRefPubMedPubMedCentral

101.

Turinsky J, Bayly BP, O'Sullivan DM. 1,2-Diacylglycerol and ceramide levels in rat skeletal muscle and liver in vivo. Studies with insulin, exercise, muscle denervation, and vasopressin. J Biol Chem. 1990;265(14):7933–8.PubMed

102.

Grazzini E, Breton C, Derick S, Andres M, Raufaste D, Rickwaert F, et al. Vasopressin receptors in human adrenal medulla and pheochromocytoma. J Clin Endocrinol Metab. 1999;84(6):2195–203. https://doi.org/10.1210/jcem.84.6.5775.CrossRefPubMed

103.

Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–64. https://doi.org/10.1152/physrev.00035.2011.CrossRefPubMed

104.

Aoyagi T, J-i B, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148(5):2075–84. https://doi.org/10.1210/en.2006-1315.CrossRefPubMed

105.

Zhu J, Chang L, Xie J, Ai H. Arginine vasopressin injected into the dorsal motor nucleus of the vagus inhibits gastric motility in rats. Gastroenterol Res Pract. 2016;2016:4618672. https://doi.org/10.1155/2016/4618672.CrossRefPubMed

106.

Xing J, Qian L, Chen J. Experimental gastric dysrhythmias and its correlation with in vivo gastric muscle contractions. World J Gastroenterol. 2006;12(25):3994–8. https://doi.org/10.3748/wjg.v12.i25.3994.CrossRefPubMedPubMedCentral

107.

Livingston EH, Passaro EP. Postoperative ileus. Dig Dis Sci. 1990;35(1):121–32. https://doi.org/10.1007/bf01537233.CrossRefPubMed

108.

Ohlsson B, Bjorgell O, Ekberg O, Darwiche G. The oxytocin/vasopressin receptor antagonist atosiban delays the gastric emptying of a semisolid meal compared to saline in human. BMC Gastroenterol. 2006;6:11. https://doi.org/10.1186/1471-230X-6-11.CrossRefPubMedPubMedCentral

109.

Caras SD, Soykan I, Beverly V, Lin Z, McCallum RW. The effect of intravenous vasopressin on gastric myoelectrical activity in human subjects. Neurogastroenterol Motil. 1997;9(3):151–6. https://doi.org/10.1046/j.1365-2982.1997.d01-37.x.CrossRefPubMed

110.

Xu X, Brining DL, Chen JDZ. Effects of vasopressin and long pulse–low frequency gastric electrical stimulation on gastric emptying, gastric and intestinal myoelectrical activity and symptoms in dogs. Neurogastroenterol Motil. 2005;17(2):236–44. https://doi.org/10.1111/j.1365-2982.2004.00616.x.CrossRefPubMed

111.

Fields CT, Chassaing B, Paul MJ, Gewirtz AT, de Vries GJ. Vasopressin deletion is associated with sex-specific shifts in the gut microbiome. Gut Microbes. 2018;9(1):13–25. https://doi.org/10.1080/19490976.2017.1356557.CrossRefPubMed

112.

Babygirija R, Zheng J, Ludwig K, Takahashi T. Central oxytocin is involved in restoring impaired gastric motility following chronic repeated stress in mice. Am J Physiol Regul Integr Comp Physiol. 2010;298(1):R157–65. https://doi.org/10.1152/ajpregu.00328.2009.CrossRefPubMed

113.

Bulbul M, Babygirija R, Ludwig K, Takahashi T. Central oxytocin attenuates augmented gastric postprandial motility induced by restraint stress in rats. Neurosci Lett. 2010;479(3):302–6. https://doi.org/10.1016/j.neulet.2010.05.085.CrossRefPubMed

114.

Buffington SA, Di Prisco GV, Auchtung TA, Ajami NJ, Petrosino JF, Costa-Mattioli M. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell. 2016;165(7):1762–75. https://doi.org/10.1016/j.cell.2016.06.001.CrossRefPubMedPubMedCentral

115.

Borg J, Melander O, Johansson L, Uvnas-Moberg K, Rehfeld JF, Ohlsson B. Gastroparesis is associated with oxytocin deficiency, oesophageal dysmotility with hyperCCKemia, and autonomic neuropathy with hypergastrinemia. BMC Gastroenterol. 2009;9:17. https://doi.org/10.1186/1471-230X-9-17.CrossRefPubMedPubMedCentral

116.

Poutahidis T, Kleinewietfeld M, Smillie C, Levkovich T, Perrotta A, Bhela S, et al. Microbial reprogramming inhibits Western diet-associated obesity. PLoS One. 2013;8(7):e68596. https://doi.org/10.1371/journal.pone.0068596.CrossRefPubMedPubMedCentral

117.

Poutahidis T, Kearney SM, Levkovich T, Qi P, Varian BJ, Lakritz JR, et al. Microbial symbionts accelerate wound healing via the neuropeptide hormone oxytocin. PLoS One. 2013;8(10):e78898. https://doi.org/10.1371/journal.pone.0078898.CrossRefPubMedPubMedCentral

118.

Rossi R, Scharrer E. Vasopressin inhibits food intake in pygmy goats by activation of alpha 1-adrenergic receptors. Pharmacol Biochem Behav. 1994;49(4):897–900. https://doi.org/10.1016/0091-3057(94)90240-2.CrossRefPubMed

119.

Connan F, Lightman SL, Landau S, Wheeler M, Treasure J, Campbell IC. An investigation of hypothalamic-pituitary-adrenal axis hyperactivity in anorexia nervosa: the role of CRH and AVP. J Psychiatr Res. 2007;41(1–2):131–43. https://doi.org/10.1016/j.jpsychires.2005.12.005.CrossRefPubMed

120.

Mozid AM, Tringali G, Forsling ML, Hendricks MS, Ajodha S, Edwards R, et al. Ghrelin is released from rat hypothalamic explants and stimulates corticotrophin-releasing hormone and arginine-vasopressin. Horm Metab Res. 2003;35(8):455–9. https://doi.org/10.1055/s-2003-41801.CrossRefPubMed

121.

Yoshimura M, Nishimura K, Nishimura H, Sonoda S, Ueno H, Motojima Y, et al. Activation of endogenous arginine vasopressin neurons inhibit food intake: by using a novel transgenic rat line with DREADDs system. Sci Rep. 2017;7(1):15728. https://doi.org/10.1038/s41598-017-16049-2.CrossRefPubMedPubMedCentral

122.

Pei H, Sutton AK, Burnett KH, Fuller PM, Olson DP. AVP neurons in the paraventricular nucleus of the hypothalamus regulate feeding. Mol Metab. 2014;3(2):209–15. https://doi.org/10.1016/j.molmet.2013.12.006.CrossRefPubMedPubMedCentral

123.

Aoyagi T, Kusakawa S, Sanbe A, Hiroyama M, Fujiwara Y, Yamauchi J, et al. Enhanced effect of neuropeptide Y on food intake caused by blockade of the V(1A) vasopressin receptor. Eur J Pharmacol. 2009;622(1–3):32–6. https://doi.org/10.1016/j.ejphar.2009.09.017.CrossRefPubMed

124.

Israel S, Lerer E, Shalev I, Uzefovsky F, Reibold M, Bachner-Melman R, et al. Molecular genetic studies of the arginine vasopressin 1a receptor (AVPR1a) and the oxytocin receptor (OXTR) in human behaviour: from autism to altruism with some notes in between. In: Neumann ID, Landgraf R, editors. Progress in Brain Research. Elsevier; 2008. p. 435–49.

125.

Blevins JE, Ho JM. Role of oxytocin signaling in the regulation of body weight. Rev Endocr Metab Disord. 2013;14(4):311–29. https://doi.org/10.1007/s11154-013-9260-x.CrossRefPubMedPubMedCentral

126.

Olszewski PK, Klockars A, Olszewska AM, Fredriksson R, Schioth HB, Levine AS. Molecular, immunohistochemical, and pharmacological evidence of oxytocin's role as inhibitor of carbohydrate but not fat intake. Endocrinology. 2010;151(10):4736–44. https://doi.org/10.1210/en.2010-0151.CrossRefPubMedPubMedCentral

127.

Borg J, Simrén M, Ohlsson B. Oxytocin reduces satiety scores without affecting the volume of nutrient intake or gastric emptying rate in healthy subjects. Neurogastroenterol Motil. 2011;23(1):56–e5. https://doi.org/10.1111/j.1365-2982.2010.01599.x.CrossRefPubMed

128.

Dallman MF, Pecoraro N, Akana SF, la Fleur SE, Gomez F, Houshyar H, et al. Chronic stress and obesity: a new view of “comfort food”. Proc Natl Acad Sci U S A. 2003;100(20):11696–701. https://doi.org/10.1073/pnas.1934666100.CrossRefPubMedPubMedCentral

129.

Wideman CH, Murphy HM. Modulatory effects of vasopressin on glucose and protein metabolism during food-restriction stress. Peptides. 1993;14(2):259–61. https://doi.org/10.1016/0196-9781(93)90039-J.CrossRefPubMed

130.

Kamoi K, Ishibashi M, Yamaji T. Thirst and plasma levels of vasopressin, angiotensin II and atrial natriuretic peptide in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1991;11(3):195–202. https://doi.org/10.1016/S0168-8227(05)80033-6.CrossRefPubMed

131.

Habtemichael EN, Alcazar-Roman A, Rubin BR, Grossi LR, Belman JP, Julca O, et al. Coordinated regulation of vasopressin inactivation and glucose uptake by action of TUG protein in muscle. J Biol Chem. 2015;290(23):14454–61. https://doi.org/10.1074/jbc.C115.639203.CrossRefPubMedPubMedCentral

132.

Gajdosechova L, Krskova K, Segarra AB, Spolcova A, Suski M, Olszanecki R, et al. Hypooxytocinaemia in obese Zucker rats relates to oxytocin degradation in liver and adipose tissue. J Endocrinol. 2014;220(3):333–43. https://doi.org/10.1530/joe-13-0417.CrossRefPubMed

133.

Colson P, Ibarondo J, Devilliers G, Balestre MN, Duvoid A, Guillon G. Upregulation of V1a vasopressin receptors by glucocorticoids. Am J Physiol Endocrinol Metab. 2006;263(6):E1054–E62. https://doi.org/10.1152/ajpendo.2006.263.6.E1054.CrossRef

134.

Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J. 1978;176(3):893–8.CrossRefPubMedPubMedCentral

135.

Keppens S, de Wulf H. The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta. 1979;588(1):63–9. https://doi.org/10.1016/0304-4165(79)90371-4.CrossRefPubMed

136.

Howl J, Ismail T, Strain AJ, Kirk CJ, Anderson D, Wheatley M. Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem J. 1991;276(1):189–95. https://doi.org/10.1042/bj2760189.CrossRefPubMedPubMedCentral

137.

Nakamura K, Aoyagi T, Hiroyama M, Kusakawa S, Mizutani R, Sanbe A, et al. Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur J Pharmacol. 2009;613(1–3):182–8. https://doi.org/10.1016/j.ejphar.2009.04.008.CrossRefPubMed

138.

Kjær A. Vasopressin as a neuroendocrine regulator of anterior pituitary hormone secretion. Acta Endocrinol. 1993;129(6):489–96. https://doi.org/10.1530/acta.0.1290489.CrossRefPubMed

139.

Le JA, Wilson HM, Shehu A, Devi YS, Aguilar T, Gibori G. Prolactin activation of the long form of its cognate receptor causes increased visceral fat and obesity in males as shown in transgenic mice expressing only this receptor subtype. Horm Metab Res. 2011;43(13):931–7. https://doi.org/10.1055/s-0031-1291182.CrossRefPubMedPubMedCentral

140.

Drissi F, Raoult D, Merhej V. Metabolic role of lactobacilli in weight modification in humans and animals. Microb Pathog. 2017;106:182–94. https://doi.org/10.1016/j.micpath.2016.03.006.CrossRefPubMed

141.

Camerino C. Low sympathetic tone and obese phenotype in oxytocin-deficient mice. Obesity. 2009;17(5):980–4. https://doi.org/10.1038/oby.2009.12.CrossRefPubMed

142.

Watanabe S, Wei F-Y, Matsunaga T, Matsunaga N, Kaitsuka T, Tomizawa K. Oxytocin protects against stress-induced cell death in murine pancreatic β-cells. Sci Rep. 2016;6:25185. https://doi.org/10.1038/srep25185.CrossRefPubMedPubMedCentral

143.

Plante E, Menaouar A, Danalache BA, Yip D, Broderick TL, Chiasson J-L, et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology. 2015;156(4):1416–28. https://doi.org/10.1210/en.2014-1718.CrossRefPubMed

144.

Dunning BE, Moltz JH, Fawcett CP. Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP). Peptides. 1984;5(5):871–5. https://doi.org/10.1016/0196-9781(84)90109-8.CrossRefPubMed

145.

Widmaier EP, Shah PR, Lee G. Interactions between oxytocin, glucagon and glucose in normal and streptozotocin-induced diabetic rats. Regul Pept. 1991;34(3):235–49. https://doi.org/10.1016/0167-0115(91)90182-g.CrossRefPubMed

146.

Warren KR, Wehring HJ, Liu F, McMahon RP, Chen S, Chester C, et al. Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. Physiol Behav. 2018;189:86–91. https://doi.org/10.1016/j.physbeh.2018.03.008.CrossRefPubMed

147.

Elabd C, Cousin W, Upadhyayula P, Chen RY, Chooljian MS, Li J, et al. Oxytocin is an age-specific circulating hormone that is necessary for muscle maintenance and regeneration. Nat Commun. 2014;5:4082. https://doi.org/10.1038/ncomms5082.CrossRefPubMedPubMedCentral

148.

Liu Y, Conboy I. Unexpected evolutionarily conserved rapid effects of viral infection on oxytocin receptor and TGF-beta/pSmad3. Skelet Muscle. 2017;7(1):7. https://doi.org/10.1186/s13395-017-0125-y.CrossRefPubMedPubMedCentral

149.

Schwartz Y, Goodman HM, Yamaguchi H. Refractoriness to growth hormone is associated with increased intracellular calcium in rat adipocytes. Proc Natl Acad Sci U S A. 1991;88(15):6790–4.CrossRefPubMedPubMedCentral

150.

Egan JJ, Saltis J, Wek SA, Simpson IA, Londos C. Insulin, oxytocin, and vasopressin stimulate protein kinase C activity in adipocyte plasma membranes. Proc Natl Acad Sci U S A. 1990;87(3):1052–6.CrossRefPubMedPubMedCentral

151.

Mukherjee SP, Mukherjee C. Stimulation of pyruvate dehydrogenase activity in adipocytes by oxytocin: evidence for mediation of the insulin-like effect by endogenous hydrogen peroxide independent of glucose transport. Arch Biochem Biophys. 1982;214(1):211–22. https://doi.org/10.1016/0003-9861(82)90024-8.CrossRefPubMed

152.

Eckertova M, Ondrejcakova M, Krskova K, Zorad S, Jezova D. Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis. Br J Pharmacol. 2011;162(2):452–63. https://doi.org/10.1111/j.1476-5381.2010.01037.x.CrossRefPubMedPubMedCentral

153.

Maejima Y, Aoyama M, Sakamoto K, Jojima T, Aso Y, Takasu K, et al. Impact of sex, fat distribution and initial body weight on oxytocin’s body weight regulation. Sci Rep. 2017;7(1):8599. https://doi.org/10.1038/s41598-017-09318-7.CrossRefPubMedPubMedCentral

154.

Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12–22. https://doi.org/10.1172/JCI77812.CrossRefPubMedPubMedCentral

155.

Nye C, Kim J, Kalhan SC, Hanson RW. Reassessing triglyceride synthesis in adipose tissue. Trends Endocrinol Metab. 2008;19(10):356–61. https://doi.org/10.1016/j.tem.2008.08.003.CrossRefPubMed

156.

Elabd C, Basillais A, Beaupied H, Breuil V, Wagner N, Scheideler M, et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells. 2008;26(9):2399–407. https://doi.org/10.1634/stemcells.2008-0127.CrossRefPubMed

157.

Liu G-S, Chan EC, Higuchi M, Dusting GJ, Jiang F. Redox mechanisms in regulation of adipocyte differentiation: beyond a general stress response. Cells. 2012;1(4):976–93. https://doi.org/10.3390/cells1040976.CrossRefPubMedPubMedCentral

158.

Drehmer DL, de Aguiar AM, Brandt AP, Petiz L, Cadena SM, Rebelatto CK, et al. Metabolic switches during the first steps of adipogenic stem cells differentiation. Stem Cell Res. 2016;17(2):413–21. https://doi.org/10.1016/j.scr.2016.09.001.CrossRefPubMed

159.

Roberts ZS, Wolden-Hanson T, Matsen ME, Ryu V, Vaughan CH, Graham JL, et al. Chronic hindbrain administration of oxytocin is sufficient to elicit weight loss in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol. 2017;313(4):R357–R71. https://doi.org/10.1152/ajpregu.00169.2017.CrossRefPubMedPubMedCentral

160.

Wu L, Meng J, Shen Q, Zhang Y, Pan S, Chen Z, et al. Caffeine inhibits hypothalamic A1R to excite oxytocin neuron and ameliorate dietary obesity in mice. Nat Commun. 2017;8:15904. https://doi.org/10.1038/ncomms15904.CrossRefPubMedPubMedCentral

161.

Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77. https://doi.org/10.1038/nrm2391.CrossRefPubMedPubMedCentral

162.

Shi H, Halvorsen Y-D, Ellis PN, Wilkison WO, Zemel MB. Role of intracellular calcium in human adipocyte differentiation. Physiol Genomics. 2000;3(2):75–82. https://doi.org/10.1152/physiolgenomics.2000.3.2.75.CrossRefPubMed

163.

Varian BJ, Poutahidis T, DiBenedictis BT, Levkovich T, Ibrahim Y, Didyk E, et al. Microbial lysate upregulates host oxytocin. Brain Behav Immun. 2017;61:36–49. https://doi.org/10.1016/j.bbi.2016.11.002.CrossRefPubMed

164.

Varian BJ, Goureshetti S, Poutahidis T, Lakritz JR, Levkovich T, Kwok C, et al. Beneficial bacteria inhibit cachexia. Oncotarget. 2016;7(11):11803–16. https://doi.org/10.18632/oncotarget.7730.CrossRefPubMedPubMedCentral

Title: Oxytocin and Vasopressin Systems in Obesity and Metabolic Health: Mechanisms and Perspectives
Authors: Cherlyn Ding
Faidon Magkos
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Obesity
Obesity
Insulins
Insulins
Published in: Current Obesity Reports / Issue 3/2019
Electronic ISSN: 2162-4968
DOI: https://doi.org/10.1007/s13679-019-00355-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2019

Nonalcoholic Fatty Liver Disease and Obesity Treatment

Gut Microbiota Dysbiosis in Human Obesity: Impact of Bariatric Surgery

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Food Preferences and Potential Mechanisms Involved

Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity

Severe Obesity in the Pediatric Population: Current Concepts in Clinical Care

Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage